According to a press release from GSK, Blenrep (belantamab mafodotin) has been authorized by the UK Medicine and Healthcare products Regulatory Agency (MHRA) “for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide.”
 
This approval was based on “superior efficacy results from the pivotal DREAMM-7 and DREAMM-8 phase III trials in relapsed or refractory multiple myeloma which support MHRA authorization of Blenrep combinations.”
 
“These include statistically significant and clinically meaningful progression-free survival (PFS) results for Blenrep combinations versus standards of care in both trials and overall survival (OS) in DREAMM-7. The safety and tolerability profiles of the Blenrep combinations were broadly consistent with the known profiles of the individual agents,” said the press release.
 
IMF Chief Medical Officer Joseph Mikhael MD, MEd, FRCPC, FACP, FASCO had this to say about the UK MHRA approval: “As patients with multiple myeloma increasingly receive combination therapies at diagnosis, treatment options available in the community setting that use different mechanisms like Blenrep are crucial to extending remission and ultimately survival. We are pleased to see this advancement in the treatment landscape extended across both academic and community settings where many patients are treated.”
 
“This UK regulatory authorization marks the first in the world for Blenrep in this treatment setting,” stated GSK.
 
To know more about Blenrep’s UK MHRA approval, read the full press release.